Midbrain dopamine function in schizophrenia and depression: a post-mortem and positron emission tomographic imaging study
Open accessThe DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.
Abstract
Elevated in vivo markers of presynaptic striatal dopamine activity have been a consistent finding in schizophrenia, and include a large effect size elevation in dopamine synthesis capacity. However, it is not known if the dopaminergic dysfunction is limited to the striatal terminals of dopamine neurons, or is also evident in the dopamine neuron cell bodies, which mostly originate in the substantia nigra. The aim of our studies was therefore to determine whether dopamine synthesis capacity is altered in the substantia nigra of people with schizophrenia, and how this relates to symptoms. In a post-mortem study, a semi-quantitative analysis of tyrosine hydroxylase staining was conducted in nigral dopaminergic cells from post-mortem tissue from patients with schizophrenia (n = 12), major depressive disorder (n = 13) and matched control subjects (n = 13). In an in vivo imaging study, nigral and striatal dopaminergic function was measured in patients with schizophrenia (n = 29) and matched healthy control subjects (n = 29) using (18)F-dihydroxyphenyl-L-alanine ((18)F-DOPA) positron emission tomography. In the post-mortem study we found that tyrosine hydroxylase staining was significantly increased in nigral dopaminergic neurons in schizophrenia compared with both control subjects (P < 0.001) and major depressive disorder (P < 0.001). There was no significant difference in tyrosine hydroxylase staining between control subjects and patients with major depressive disorder, indicating that the elevation in schizophrenia is not a non-specific indicator of psychiatric illness. In the in vivo imaging study we found that (18)F-dihydroxyphenyl-L-alanine uptake was elevated in both the substantia nigra and in the striatum of patients with schizophrenia (effect sizes = 0.85, P = 0.003 and 1.14, P < 0.0001, respectively) and, in the voxel-based analysis, was elevated in the right nigra (P < 0.05 corrected for family wise-error). Furthermore, nigral (18)F-dihydroxyphenyl-L-alanine uptake was positively related with the severity of symptoms (r = 0.39, P = 0.035) in patients. However, whereas nigral and striatal (18)F-dihydroxyphenyl-L-alanine uptake were positively related in control subjects (r = 0.63, P < 0.001), this was not the case in patients (r = 0.30, P = 0.11). These findings indicate that elevated dopamine synthesis capacity is seen in the nigral origin of dopamine neurons as well as their striatal terminals in schizophrenia, and is linked to symptom severity in patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“These techniques indicate that striatal dopamine synthesis, storage and release are elevated in patients with psychosis compared to healthy controls (HC) (45-48) with large effect sizes (49).”
From Aberrant Salience, Information Processing, and Dopaminergic Signaling in People at Clinical High Risk for Psychosis (2020) · cites this paper as [48]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data
Patlak, C. S., Blasberg, R. G., & Fenstermacher, J. D. (1983) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1983.1 · Cited by 3,567 · cited 1×
“A Patlak graphical analysis was used to calculate the influx constant (K cer i value) for the specific uptake of 18 F-DOPA in the regions of interest relative to uptake in the reference region (Patlak et al., 1983).”
The Dopamine Hypothesis of Schizophrenia: Version III--The Final Common Pathway
Howes, O. D., & Kapur, S. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp006 · Cited by 2,693
Self-citationDopamine in schizophrenia: a review and reconceptualization
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.11.1474 · Cited by 2,018 · cited 1×
“The dopamine hypothesis of schizophrenia proposes that subcortical dopamine dysfunction underlies the illness (Davis et al., 1991; Howes and Kapur, 2009).”
Haber, S. N., Fudge, J. L., & McFarland, N. R. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-06-02369.2000 · Cited by 1,610 · cited 1×
“…evidence indicates that these alterations in dopamine function are particularly apparent in the associative subdivision of the striatum (Howes et al., 2009b; Kegeles et al., 2010), which predominantly receives projections from the substantia nigra (Haber et al., 2000, 2006; Joel and Weiner, 2000).”
Laruelle, M., Abi-Dargham, A., van Dyck, C. H., Gil, R., D'Souza, C. D., Erdos, J., McCance, E., Rosenblatt, W., Fingado, C., Zoghbi, S. S., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.17.9235 · Cited by 1,291 · cited 2×
“…al., 2012; Roiser et al., 2012; Yoon et al., 2013) and the consistent evidence for increased dopamine release in the striatal terminal regions [see (Laruelle et al., 1996; Breier et al., 1997; Abi-Dargham et al., 2000) and meta-analysis (Howes et al., 2012b)], it seems likely that this reflects an…”
Ollinger, J. M., & Fessler, J. A. (1997) · IEEE Signal Processing Magazine · doi:10.1109/79.560323 · Cited by 1,167
Breier, A., Su, T.-P., Saunders, R., Carson, R. E., Kolachana, B. S., de Bartolomeis, A., Weinberger, D. R., Weisenfeld, N., Malhotra, A. K., Eckelman, W. C., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.6.2569 · Cited by 1,154 · cited 2×
“…Kumakura et al., 2007; Bose et al., 2008; Howes et al., 2009b; Nozaki et al., 2009; Shotbolt et al., 2011; Demjaha et al., 2012), and elevated baseline and stimulated striatal dopamine levels (Laruelle et al., 1996; Breier et al., 1997; Abi-Dargham et al., 1998, 2000, 2009; Mizrahi et al., 2012).”
Increased baseline occupancy of D 2 receptors by dopamine in schizophrenia
Abi-Dargham, A., Rodenhiser, J., Printz, D., Zea-Ponce, Y., Gil, R., Kegeles, L. S., Weiss, R., Cooper, T. B., Mann, J. J., Van Heertum, R. L., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.14.8104 · Cited by 1,020 · cited 2×
“…2013) and the consistent evidence for increased dopamine release in the striatal terminal regions [see (Laruelle et al., 1996; Breier et al., 1997; Abi-Dargham et al., 2000) and meta-analysis (Howes et al., 2012b)], it seems likely that this reflects an increase in midbrain dopamine neuron…”
Howes, O. D., Kambeitz, J., Kim, E., Stahl, D., Slifstein, M., Abi-Dargham, A., & Kapur, S. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2012.169 · Cited by 967 · cited 3×
“In the schizophrenia group the mean (SD) symptom severity scores were: total symptoms = 77.6 (47.6); positive symptoms = 38.3 (30); affective symptoms = 2.0 (3.9); negative symptoms = 31.9 (22.9).”
InfluentialSelf-citationIncreased Striatal Dopamine Transmission in Schizophrenia: Confirmation in a Second Cohort
Abi-Dargham, A., Gil, R., Krystal, J., Baldwin, R. M., Seibyl, J. P., Bowers, M., van Dyck, C. H., Charney, D. S., Innis, R. B., & Laruelle, M. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.6.761 · Cited by 803 · cited 1×
“…Kumakura et al., 2007; Bose et al., 2008; Howes et al., 2009b; Nozaki et al., 2009; Shotbolt et al., 2011; Demjaha et al., 2012), and elevated baseline and stimulated striatal dopamine levels (Laruelle et al., 1996; Breier et al., 1997; Abi-Dargham et al., 1998, 2000, 2009; Mizrahi et al., 2012).”
Research works printed but not linked: 3
- Andreasen NC. Comprehensive assessment of symptoms and history. Iowa: University of Iowa College of Medicine; 1987. [Google Scholar]
- Asselin MCH, Howes OD, Osman S, Yau K, Grasby PM. Increase in striatal f-DOPA influx constants in patients at ultra high risk of psychosis are not due to changes in plasma OMFD concentrations. J Cereb Blood Flow Metab. 2007;27:PO01–03M. [Google Scholar]
- Howes OD, Kambeitz J, Kim E, Stahl D, Slifstein M, Abi-Dargham A, et al. The nature of dopamine dysfunction in schizophrenia and what this means for treatment: meta-analysis of imaging studies. Arch Gen Psychiatry. 2012b;69:776–86. doi: 10.1001/archgenpsychiatry.2012.169. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI · Paper page
Cited by
Items 101–199 of 199
D’Ambrosio, E., Pergola, G., Pardiñas, A. F., Dahoun, T., Veronese, M., Sportelli, L., Taurisano, P., Griffiths, K., Jauhar, S., Rogdaki, M., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-16442-6 · Cited by 14
Self-citationCruz, J. A. D. D., Schmidt‐Kastner, R., Stevens, J., Steinbusch, H. W. M., & Rutten, B. P. F. (2014) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2014.07.001 · Cited by 16
“Given that a wealth of findings in the literature has indicated that the dopaminergic neurotransmission system is centrally involved in psychosis (Howes et al., 2013; van Os et al., 2010) and other psychiatric disorders, it is timely to explore the expression of hypoxia-regulated genes such as the HIF-1 in dopaminergi…”
Uzuneser, T. C., Schindehütte, M., Dere, E., von Hörsten, S., Kornhuber, J., Grömer, T. W., & Müller, C. P. (2018) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2018.09.005 · Cited by 14
Amphetamine-induced striatal dopamine release in schizotypal personality disorder
Thompson, J. L., Rosell, D. R., Slifstein, M., Xu, X., Rothstein, E. G., Modiano, Y. A., Kegeles, L. S., Koenigsberg, H. W., New, A. S., Hazlett, E. A., et al. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05561-5 · Cited by 13
“However, it is clear from molecular imaging studies that, although schizophrenia is associated with elevated presynaptic striatal DA functioning, there is heterogeneity across schizophrenia participants in these DA measures (Bonoldi and Howes 2013).”
BackgroundKos, M. Z., Duan, J., Sanders, A. R., Blondell, L., Drigalenko, E. I., Carless, M. A., Gejman, P. V., Göring, H. H. H., MGS, Gejman, P. V., et al. (2018) · Translational Psychiatry · doi:10.1038/s41398-018-0325-1 · Cited by 14
Resolving the heterogeneity of dopamine subsystems dysfunction in schizophrenia: a PET meta-analysis
Zhao, Z. W., Li, X., Xie, Y., Lin, L., Wei, L., Chang, Z., Luo, Y., Dong, H., Zhang, X., Dong, Q., et al. (2025) · Schizophrenia · doi:10.1038/s41537-025-00684-0 · Cited by 12
Increased NigralSLC6A3Activity in Schizophrenia Patients: Findings From the Toronto–McLean Cohorts
Kennedy, J. L., Xiong, N., Yu, J., Zai, C. C. H., Pouget, J. G., Li, J., Liu, K., Qing, H., Wang, T., Martin, E. R., et al. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbv191 · Cited by 13
Tomasella, E., Falasco, G., Urrutia, L., Bechelli, L., Padilla, L., & Gelman, D. M. (2020) · EJNMMI Research · doi:10.1186/s13550-020-00629-x · Cited by 12
“It has been reported that the expression of TH, the rate-limiting enzyme of dopamine synthesis, is increased in the substantia nigra (SN) of schizophrenia patients [39].”
BackgroundVenkataramaiah, C., Priya, B. L., & Rajendra, W. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1765875 · Cited by 14
“…have shown patients with schizophrenia show increases in subcortical synaptic dopamine content (Abi-Dargham et al., 2000), abnormally high dopamine release after amphetamine treatment (Breier et al., 1997) and increased basal dopamine synthesis (Howes et al., 2013) compared with healthy controls.”
BackgroundGoodman, M. S., Bridgman, A. C., Rabin, R. A., Blumberger, D. M., Rajji, T. K., Daskalakis, Z. J., George, T. P., & Barr, M. S. (2016) · Brain stimulation · doi:10.1016/j.brs.2016.11.004 · Cited by 12
“Third, several lines of evidence exist that implica te the role of dopamine in both schizophrenia pathophysiology [23, 61] as well as in cannabis use [62-64].”
BackgroundOuyang, W., Sun, G., & Hsu, M. (2019) · Aggression and Violent Behavior · doi:10.1016/j.avb.2019.101347 · Cited by 13
Li, Z., Mukherjee, D., Duric, B., Austin-Zimmerman, I., Trotta, G., Spinazzola, E., Quattrone, D., Murray, R. M., & Forti, M. D. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02668-5 · Cited by 12
Victoriano, G. M., Zhu, Y., Middleton, F. A., Massa, P. T., Ajulu, K., Webster, M. J., & Weickert, C. S. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.116141 · Cited by 11
“…Meyer et al., 2001; Moriya et al., 2020; Roy et al., 1989), Howes et al. found no change in TH expression in the SN from major depressive disorder patients (Howes et al., 2013), suggesting that the dopamine disruption found in major depressive disorder may be unrelated to TH levels of the midbrain.”
InfluentialTyrosine hydroxylase localization in the nucleus accumbens in schizophrenia
McCollum, L. A., McCullumsmith, R. E., & Roberts, R. C. (2016) · Brain Structure and Function · doi:10.1007/s00429-015-1174-9 · Cited by 12
“This study examined postmortem human tissue to determine if abnormalities are present in dopamine synthesis in the NAcc in SZ.”
BackgroundSchizophrenia-associated changes in neuronal subpopulations in the human midbrain
Alsema, A. M., Puvogel, S., Kracht, L., Webster, M. J., Weickert, C. S., Eggen, B. J. L., & Sommer, I. E. (2024) · Brain · doi:10.1093/brain/awae321 · Cited by 10
“45,54,55 We emphasize that we examined NEUN+ dopamine neurons, representing only a subset of dopamine neurons, including those expressing ALDH1A1 and others that may co-synthesize glutamate.”
Evenamide reverses schizophrenia-related dysfunction in a neurodevelopmental animal model
Uliana, D. L., Walsh, R. A., Fabris, D., & Grace, A. A. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-025-02188-y · Cited by 9
“This domain in MAM rats is proposed to parallel the increased fl uorodopa uptake observed in the associative striatum of patients with schizophrenia [29, 54, 55].”
Varga, T. G., Simões, J. G. D. T., Siena, A., Henrique, E., da Silva, R. C. B., Bioni, V. S., Ramos, A. C., & Rosenstock, T. R. (2021) · Psychopharmacology · doi:10.1007/s00213-021-05880-1 · Cited by 9
Agboola, J. B., Ehigie, A. F., Ehigie, L. O., Ojeniyi, F. D., & Olayemi, A. A. (2022) · Journal of Food Biochemistry · doi:10.1111/jfbc.14115 · Cited by 10
Lee, D., Seo, J., Jeong, H. C., Lee, H., & Lee, S. B. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.756613 · Cited by 10
Chandra, J. J., Zhu, Y., Petty, A. E., Kostoglou, Y., Haynes, W. X., Webster, M. J., & Weickert, C. S. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03359-7 · Cited by 9
“Recent studies have demonstrated dopamine dysfunction further extends to other regions of the midbrain, encompassing excessive dopamine production by nigrostriatal dopamine neurons projecting from the substantia nigra to the dorsal striatum [5, 6].”
Howes, O. D., Vano, L. J., Petty, A. E., Rutigliano, G., Halff, E. F., Veronese, M., Kaar, S. J., Nordio, G., Lopes, E. F., Cragg, S. J., et al. (2025) · Biological Psychiatry · doi:10.1016/j.biopsych.2025.10.013 · Cited by 9
Self-citationGrace, A., & Uliana, D. L. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03513-7 · Cited by 8
“…important because the lateral VTA projects to the associative striatum, which is the striatal region shown to have increased amphetamine-induced dopamine release that correlates with worsening of psychosis [69] and where there is an increase in fl uorodopa uptake in schizophrenia patients [70, 71].”
Górny, M., Bilska‐Wilkosz, A., Iciek, M., Rogóż, Z., & Lorenc‐Koci, E. (2023) · FEBS Journal · doi:10.1111/febs.16944 · Cited by 10
Lin, Y., Zhang, L. J., Ying, L., & Zhou, Q. (2020) · BMC Psychiatry · doi:10.1186/s12888-020-02744-4 · Cited by 8
Chakrabarty, T., McInerney, S. J., Torres, I. J., Frey, B. N., Milev, R. V., Müller, D. J., Rotzinger, S., Kennedy, S. H., Lam, R. W. M., & the CAN-BIND Investigator Team (2021) · CNS Drugs · doi:10.1007/s40263-021-00793-1 · Cited by 9
“Schizophrenia and MDD differ in basal striatal dopamine functioning, potentially resulting in differential modulation of striatal dopamine activity by aripiprazole and consequently different (and in MDD, potentially detrimental) effects on motor-based cognitive functions such as reaction time [47, 48].”
BackgroundPresynaptic Dopaminergic Function: Implications for Understanding Treatment Response in Psychosis
Bonoldi, I., & Howes, O. D. (2014) · CNS Drugs · doi:10.1007/s40263-014-0177-z · Cited by 9
“Recent studies here suggest that there is altered dopaminergic function in the midbrain in schizophrenia as well as in the striatum [78, 79].”
BackgroundSelf-citationGray Matter Iron and Neuromelanin in Psychosis: A Systematic Review and Meta-Analysis of MRI Studies
Vano, L. J., Sedlacik, J., Carr, R., Bukala, B. R., Howes, O. D., & McCutcheon, R. A. (2026) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20251257 · Cited by 6
Self-citationMental disorders in entangled brains
Aftab, A. (2023) · Philosophical Psychology · doi:10.1080/09515089.2023.2217219 · Cited by 5
“A classic example of that would be schizophrenia, where elevated in vivo markers of presynaptic striatal dopamine activity have been consistently reported, and the elevation in dopamine synthesis capacity shows a large effect size (Howes et al., 2012, 2013).”
BackgroundQiu, Y., Liu, G., Li, J., Zhou, D., Liu, Y., Guo, Z., Ye, F., Chen, F., & Peng, P. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.09.060 · Cited by 6
Theories of the pathogenesis of schizophrenia
Dąbrowska, J., Wójcik, M., Szarpak, J., Bator, D., Milanowska, J., & Nieścior, H. (2020) · Journal of Education Health and Sport · doi:10.12775/jehs.2020.10.08.039 · Cited by 5
“nigra of patients with schizophrenia compared to patients with depression and healthy controls [18].”
BackgroundAyesha, K., Zahid, S., Hasan, B., Asif, A. R., & Ahmed, N. (2023) · Molecular Biology Reports · doi:10.1007/s11033-023-08431-3 · Cited by 5
Chandra, J. J. (2024) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2024.100796 · Cited by 5
“…dysregulation may be more prominent in other brain regions such as the midbrain, whereby excessive dopamine production, underlying psychotic symptoms of schizophrenia, may further exacerbate neurotoxicity through increased reactive oxygen species generation (Howes et al., 2013; Grima et al., 2003).”
BackgroundTime varying dynamics of hallucinations in clinical and non-clinical voice-hearers
Marschall, T. M., Koops, S., Brederoo, S., Cabral, J., Ćurĉić‐Blake, B., & Sommer, I. E. (2023) · NeuroImage Clinical · doi:10.1016/j.nicl.2023.103351 · Cited by 6
“Interestingly, non-clinical voice-hearers seem to resemble healthy individuals more than clinical voice-hearers in terms of dopamine synthesis capacity (Howes et al., 2013b,a).”
Discovery of novel blood–brain barrier neuropathology in schizophrenia and bipolar disorder midbrain
Zhu, Y., Victoriano, G. M., Webster, M. J., Middleton, F. A., Massa, P. T., Fuller, C., & Weickert, C. S. (2026) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2026.106292 · Cited by 5
Thiagarajan, S. K., Mok, S. Y., Ogawa, S., Parhar, I. S., & Tang, P. Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24044088 · Cited by 4
Abayomi, O., Amato, D., Bailey, C. C., Bitanihirwe, B. K. Y., Bowen, L., Burshtein, S., Cullen, A. E., Fusté, M., Herrmann, A. P., Khodaie, B., et al. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.08.032 · Cited by 6
“Oliver Howes (King's College, London, UK) investigated the relationship between presynaptic dopamine function and clinical outcomes in people who met UHR criteria, in people who experienced long term sub-clinical symptoms and in patients with schizophrenia (Demjaha et al., 2012; Howes et al., 2013; Egerton et al., 201…”
Leptin Methylation and mRNA Expression Associated With Psychopathology in Schizophrenia Inpatients
Song, J., Chen, Y., Zhao, Q., Li, H., Li, W., Chen, K., Yu, J., Fu, W., & Chen, D. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.793910 · Cited by 4
Reid, M. J., Rogdaki, M., Polit, L. D., Hanger, B., Sabad, K., Nagy, R., Adhya, D., Baron‐Cohen, S., McAlonan, G. M., Price, J., et al. (2022) · Schizophrenia Research · doi:10.1016/j.schres.2022.05.010 · Cited by 5
“Dysregulation of genes associated with dopamine synthesis, storage and release has been identified in the midbrain of schizophrenic individuals in post-mortem studies, but not consistently reported (Howes et al., 2013; Perez-Costas et al., 2012; Purves-Tyson et al., 2017).”
Self-citationPetty, A. E., Garcia-Hidalgo, A., Halff, E. F., Natesan, S., Withers, D. J., Irvine, E. E., Kokkinou, M., Wells, L. A., Bonsall, D. R., Tang, S.-P., et al. (2023) · Molecular Imaging and Biology · doi:10.1007/s11307-023-01865-y · Cited by 4
“Additionally, an 18 F-DOPA PET study found that DA synthesis capacity was elevated in the nigra of people with schizophrenia compared to healthy controls, as well as in the striatum [13].”
BackgroundResultInfluentialSelf-citationMagnesium and Zinc in Schizophrenia
Nechifor, M. (2025) · Biomedicines · doi:10.3390/biomedicines13092249 · Cited by 3
“Additionally, the activity of tyrosine hydroxylase, the enzyme involved in the synthesis of catecholamines, is elevated [37].”
Salutogenesis concept for hospice design
Gromova, A. S., & Litvinova, O. G. (2021) · Vestnik Tomskogo gosudarstvennogo arkhitekturno-stroitel nogo universiteta JOURNAL of Construction and Architecture · doi:10.31675/1607-1859-2021-23-2-9-23 · Cited by 3
Yao, J., Zhou, Z., Tong, Q., Li, L., Wei, J., Lü, J., Hu, S., Bao, A., & He, H. (2025) · Psychoradiology · doi:10.1093/psyrad/kkaf012 · Cited by 3
“Nonetheless, such investigations remain scarce, with the current literature limited to a combination of imm unohistoc hemistry and positr on emission tomogr a-phy (PET) analysis on postmortem cohorts (Ho w es et al. , 2013 ).”
Victoriano, G. M., Zhu, Y., Neuhaus, L., Shaik, S., Middleton, F. A., Kondo, Y., Fayyazuddin, A., Hoeppner, D. J., Puvogel, S., Alsema, A. M., et al. (2025) · Biological Psychiatry Global Open Science · doi:10.1016/j.bpsgos.2025.100650 · Cited by 3
“Recent findings have demonstrated presynaptic dopaminergic dysfunction (17,18,26), reduced inhibitory interneuron markers and GABAergic (gamma-aminobutyric acidergic) receptor mRNAs (17), and elevated glutamatergic receptor mRNAs (27) in the SN of individuals with schizophrenia.”
Connectivity alterations of mesostriatal pathways in first episode psychosis
Hayward, N., Triana, A. M., Panula, J. M., Kieseppä, T., Suvisaari, J., & Raij, T. T. (2023) · Schizophrenia · doi:10.1038/s41537-023-00339-y · Cited by 2
Hashmi, A. N., Dharejo, R. A., Taj, R., Ajmal, M., Khan, N., Agha, Z., Qamar, R., & Azam, M. (2023) · International Journal of Neuroscience · doi:10.1080/00207454.2023.2251661 · Cited by 2
Deng, L., Wei, W., Qiao, C., Yin, Y., Li, X., Yu, H., Jian, L., Ma, X., Zhao, L., Wang, Q., et al. (2024) · Psychological Medicine · doi:10.1017/s0033291724000655 · Cited by 2
Bilgrami, Z. R., Kostek, N. T., Kim, I. T., Kraut, R., Kim, J. K., & Corcoran, C. M. (2020) · Springer eBooks · doi:10.1007/978-3-030-19847-3_14 · Cited by 2
Dopamine and Response to Antipsychotic Medication
Ntephe, C., & Demjaha, A. (2020) · Springer eBooks · doi:10.1007/978-3-030-57231-0_14 · Cited by 2
Dopamine mechanisms in learning and memory: evidence from rodent studies
Cruz, J. A. D. A. D. (2014) · Research Publications (Maastricht University) · doi:10.26481/dis.20140320jd · Cited by 2
Zhao, L., Tang, P., Fan, H., Hao, M., Yao, X., Li, W., Liu, L., & Liu, H. (2025) · BMC Psychiatry · doi:10.1186/s12888-025-06974-2 · Cited by 1
“These systems and areas are intimately connected to the development of psychiatric disorders, including schizophrenia [12].”
Neuropharmacological targets for schizophrenia treatment: An update
de Lima, C. A. C., Barbosa, M. E. O., de Souza-Júnior, F. J. C., Farias, S. V., Fontes-Júnior, E. A., & Maia, C. D. S. F. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111580 · Cited by 1
Hamati, R., Kanaa, N., Chidiac, B., Guimond, S., Cassidy, C., & Tuominen, L. J. (2026) · Schizophrenia · doi:10.1038/s41537-026-00731-4 · Cited by 1
“This aligns with previous NM-MRI and PET studies where dopamine activity in the SN/VTA complex correlates with positive symptoms in schizophrenia and clinical high-risk in some, but not all, reports 25,30,34,41,64,65 .”
The potential of neuromelanin-sensitive MRI in psychiatric disorders
Neutelings, E., van de Giessen, E., de Haan, L., & van der Pluijm, M. (2026) · Neuroscience Applied · doi:10.1016/j.nsa.2026.106994 · Cited by 1
“Schizophrenia can be linked to dysregulation of dopamine neurotransmission (Stone et al., 2009; Howes and Kapur, 2009; Howes et al., 2013; Jauhar et al., 2017) Hyperdopaminergic activity in the mesolimbic pathway, manifested as increased dopamine synthesis capacity and dopamine release, is thought…”
Kielhold, M. L., Jacobs, D. S., Pacheco, A. T., Lefner, M. J., Bogachuk, A. P., Lebowitz, J. J., Langdon, A., Williams, J. T., Zweifel, L. S., & Moghaddam, B. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03632-1 · Cited by 1
Li, J., Li, Y., Lin, S., Rao, J., & Zhao, H. (2026) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1014323 · Cited by 1
Williams, M. R. (2021) · Springer eBooks · doi:10.1007/978-3-030-68308-5_5 · Cited by 2
Self-citationBrown, N. K., Roche, J. K., Farmer, C. B., & Roberts, R. C. (2023) · Journal of Neural Transmission · doi:10.1007/s00702-023-02593-x · Cited by 1
“In a study that combined postmortem work and in vivo imaging of the SN, reported that tyrosine hydroxylase levels were increased in postmortem SN from schizophrenia patients but not depressed patients, and dopamine synthesis capacity was increased in drug free SZ patients (Howes et al. 2013).”
BackgroundInfluentialThe Role of Dopamine in Schizophrenia, Depression, and Addiction
杨, 成. (2023) · Advances in Social Sciences · doi:10.12677/ass.2023.124230 · Cited by 1
Schoonover, K. E., & Roberts, R. C. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/343178 · Cited by 1
“Our sample size was small and as is typical for postmortem investigations, none of our subjects were first-episode and/or antipsychotic-naïve (Schoonover et al. 2017; Howes et al. 2013).”
ResultGrannan, M. D. (2016) · Cited by 1
Petty, A. E. (2019) · The University of Queensland · doi:10.14264/uql.2019.881 · Cited by 1
Dinh, T., Nerland, S., Maximov, I. I., Barth, C., Vernon, A. C., Agartz, I., & Jørgensen, K. N. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.06.20.496804 · Cited by 1
Hui, P. (2015) · MacSphere (McMaster University) · doi:10.71548/20544
Pan, B. (2016) · Research Online (University of Wollongong)
Ahmed, J. J. (2017) · Digital Commons - University of South Florida (University of South Florida)
Fonteneau, C. (2018) · theses.fr (ABES) · doi:10.70675/b06abc42zba9az4c0bz8cbfzef0dd775e14e · Cited by 1
Structural and functional neuroimaging of schizophrenia
Diaconescu, A. O., Iglesias, S., & Stephan, K. E. (2020) · doi:10.1093/med/9780198713005.003.0060
A Preliminary Study of the Nociceptin Receptor System in Individuals with Psychosis
Khan, M. S. (2019) · TSpace (University of Toronto) · Cited by 1
Schizophrenia: Current Hypotheses, Treatments, and Future Directions
Aadland, J. A. (2020) · Figshare · doi:10.15786/13701127
Croy, E. (2020) · Otago University Research Archive (University of Otago) · Cited by 2
Williams, M. R. (2021) · Springer eBooks · doi:10.1007/978-3-030-68308-5_9
Self-citationΔιαταραχές ψυχικής υγείας σχετιζόμενες με τροφιμογενή παράσιτα
Χριστοδουλάκου, Σ.-Μ. (2020) · Institutional Repository Hellanicus
Williams, M. R. (2021) · Springer eBooks · doi:10.1007/978-3-030-68308-5_1
Self-citationWan, C., Zhang, J., Lin, Y., Zhao, K., Luo, J., Tan, J., & Zhao, X. (2020) · Research Square · doi:10.21203/rs.3.rs-23475/v1
“Not all integrated therapeutic approaches are proved to be feasible to both of patients with depression or schizophrenia, and the outcomes imply that there are some differences in the pathogenesis of depression or schizophrenia[19,20].”
BackgroundLabusga, M. (2023) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-9734
Marques, J. H. (2023) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2023.tde-05062023-141601
Silva, L. (2022) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.42.2022.tde-08082023-101118
The dual hit hypothesis of schizophrenia
Guerrin, C. G. J. (2023) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.791866719
“Maternal weight and body temperature (measured on the flank with an infrared thermometer, Pro’s Kit, MT-4612 MT-4612 ) were”
van Hooijdonk, C. F. M. (2023) · Research Publications (Maastricht University) · doi:10.26481/dis.20231201ch
Zhou, Z., Jones, K., Ivleva, E. I., & Colón-Pérez, L. M. (2025) · eNeuro · doi:10.1523/eneuro.0361-24.2025
“In addition, PET studies in individuals with schizophrenia demonstrate elevated dopamine synthesis capacity in the substantia nigra, another hub region of the midbrain, which in turn is associated with symptom severity in schizophrenia (Howes et al., 2013).”
Dopamine dysfunction in psychosis
McCutcheon, R. A., & Zauchenberger, C.-Z. (2025) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-443-29867-7.00035-9
Molecular Evidence Underlying the Dopamine Hypothesis of Schizophrenia
Çaykara, B. (2026) · Psikiyatride Guncel Yaklasimlar - Current Approaches in Psychiatry · doi:10.18863/pgy.1646228
Richardson, B. (2023) · Memorial University Research Repository (Memorial University) · doi:10.48336/6krt-h288 · Cited by 1
Petty, A. E., Glass, L. J., Rothmond, D. A., Purves-Tyson, T. D., Sweeney, A., Kondo, Y., Kubo, S., Matsumoto, M., & Weickert, C. S. (2022) · Figshare · doi:10.6084/m9.figshare.20324767
Purves-Tyson, T. D., Brown, A. M., Weissleder, C., Rothmond, D. A., & Shannon-Weickert, C. (2021) · Figshare · doi:10.6084/m9.figshare.14853387
Rauer, L. (2021) · heiDOK (Heidelberg University) · doi:10.11588/heidok.00029269
Neuroinflammation, the blood-brain barrier and immune cell trafficking in schizophrenia
Cai, H. (2019) · UNSWorks (University of New South Wales, Sydney, Australia) · doi:10.26190/unsworks/3854
Goutaudier, R. (2022) · theses.fr (ABES) · doi:10.70675/6619b466z54bfz41e3z8a90zf0967825d579
Avanesyan, H., Parsadanyan, M. A., Shahinyan, M. A., Багдасарович, Л. А., Mikaelyan, M. S., Grigoryan, S. V., & Vardevanyan, P. O. (2025) · Neurophysiology · doi:10.1007/s11062-026-10001-9 · Cited by 1
“On the other hand, dopamine hyperactivity and elevated synthesis correlate with the severity of symptoms [50, 110, 112].”
Metabolomics and Psychological and Mental Illness
Li, Z., Zhu, Z., Wang, D., & Zhang, H. (2026) · Springer eBooks · doi:10.1007/978-981-95-9567-9_8
Mancini, V., Rogdaki, M., Jauhar, S., Moretto, M., Veronese, M., Turkheimer, F., Howes, O. D., & McCutcheon, R. A. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03839-2
Self-citationNavaneethan, B., Costa, P. A., Debs, S. R., Gavljak, I., Conn, I., Penklis, A. G., Weickert, C. S., & Purves-Tyson, T. D. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111933
Li, Y., Oishi, N., Dai, Q., Nakagami, Y., Yao, L., Kawashima, T., Yoshihara, Y., Kubota, M., Nakamura, Y., Koike, S., et al. (2026) · Schizophrenia · doi:10.1038/s41537-026-00795-2
“…ict in psychosis studies by bridging the animal fi ndings that have historically emphasized the role of the ventral midbrain – striatum in dopamine dysregulation 9,13,69 , and recent human PET studies that have revealed excess dopamine synthesis not in the ventral but in the dorsal striatum 66,70 .”
Lost in translation: why don't dopamine D2 antagonists cure addictions?
Leyton, M., & Palaniyappan, L. K. (2026) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn-2026-0097
Transdiagnostic Mechanisms Underlying Nonaffective Psychosis: A Role for Hippocampal Networks?
Kaplan, C., Perepezko, K., Pontone, G. M., & Bakker, A. (2026) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2026.10.010
Engel, M. (2014) · Research Online (University of Wollongong)
Metadata
- Authors
- Howes, O. D., Williams, M., Ibrahim, K., Leung, G., Egerton, A., McGuire, P. K., & Turkheimer, F.
- Affiliations
- King's College London (GB)
- Hammersmith Hospital (GB)
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-10-03
- Volume
- 136
- Issue
- 11
- Pages
- 3242-3251
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC3808688
- OpenAlex
- W2148486359
- Cited by
- 198
- References
- 81
- Citations by year
- 2026: 13 · 2025: 14 · 2024: 11 · 2023: 23 · 2022: 19 · 2021: 15 · 2020: 24 · 2019: 20 · 2018: 14 · 2017: 10 · 2016: 16 · 2015: 8 · 2014: 11
- FWCI
- 8.30
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Brain (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion)
- Funders
- Starr Foundation
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Keywords
- schizophrenia, major depressive disorder, midbrain dopamine, substantia nigra, striatum, dopamine synthesis capacity, tyrosine hydroxylase, 18F-DOPA PET, dopaminergic dysfunction, symptom severity, postmortem brain, dopaminergic neurons, dopamine signaling, neuroimaging biomarkers
- MeSH terms
- Adult, Depressive Disorder, Major, Major Depressive Disorder, Dihydroxyphenylalanine, Dopamine, Female, Humans, Male, Middle Aged, Schizophrenia, Substantia Nigra, Tissue Banks, Tyrosine 3-Monooxygenase, Dopamine Agents, Neostriatum, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.